IKT Valuation

Inhibikase Therapeutics Inc

Add to Watchlist

Advanced Chart

1.500

+0.01(0.671%)1D

IKT Relative Valuation

IKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IKT is overvalued; if below, it's undervalued.

Historical Valuation

Inhibikase Therapeutics Inc (IKT) is now in the Fair zone, suggesting that its current forward PS ratio of 1.50 is considered Fairly compared with the five-year average of -3.32. The fair price of Inhibikase Therapeutics Inc (IKT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.50

Fair

-2.44

Trailing

Forward

0.00

EV/EBITDA

Inhibikase Therapeutics Inc. (IKT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.40

EV/EBIT

Inhibikase Therapeutics Inc. (IKT) has a current EV/EBIT of -0.40. The 5-year average EV/EBIT is -1.69. The thresholds are as follows: Strongly Undervalued below -10.28, Undervalued between -10.28 and -5.98, Fairly Valued between 2.61 and -5.98, Overvalued between 2.61 and 6.91, and Strongly Overvalued above 6.91. The current Forward EV/EBIT of -0.40 falls within the Historic Trend Line -Fairly Valued range.

1.50

Inhibikase Therapeutics Inc. (IKT) has a current PS of 1.50. The 5-year average PS is 27.39. The thresholds are as follows: Strongly Undervalued below -44.76, Undervalued between -44.76 and -8.68, Fairly Valued between 63.47 and -8.68, Overvalued between 63.47 and 99.54, and Strongly Overvalued above 99.54. The current Forward PS of 1.50 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Inhibikase Therapeutics Inc. (IKT) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.12. The thresholds are as follows: Strongly Undervalued below -5.47, Undervalued between -5.47 and -3.30, Fairly Valued between 1.05 and -3.30, Overvalued between 1.05 and 3.22, and Strongly Overvalued above 3.22. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Inhibikase Therapeutics Inc. (IKT) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.30. The thresholds are as follows: Strongly Undervalued below -2.15, Undervalued between -2.15 and -1.23, Fairly Valued between 0.63 and -1.23, Overvalued between 0.63 and 1.55, and Strongly Overvalued above 1.55. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Inhibikase Therapeutics Inc (IKT) has a current Price-to-Book (P/B) ratio of 1.40. Compared to its 3-year average P/B ratio of -3.38 , the current P/B ratio is approximately -141.27% higher. Relative to its 5-year average P/B ratio of -1.20, the current P/B ratio is about -216.02% higher. Inhibikase Therapeutics Inc (IKT) has a Forward Free Cash Flow (FCF) yield of approximately -0.18%. Compared to its 3-year average FCF yield of -109.68%, the current FCF yield is approximately -99.84% lower. Relative to its 5-year average FCF yield of -80.61% , the current FCF yield is about -99.78% lower.

1.40

P/B

Median3y

-3.38

Median5y

-1.20

-0.18

FCF Yield

Median3y

-109.68

Median5y

-80.61

Competitors Valuation Multiple

The average P/S ratio for IKT's competitors is 4.26, providing a benchmark for relative valuation. Inhibikase Therapeutics Inc Corp (IKT) exhibits a P/S ratio of 1.50, which is -64.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IKT.O

Inhibikase Therapeutics Inc

Alterity Therapeutics Ltd

5.33

62.71M

ANEB.O

Anebulo Pharmaceuticals Inc

Atara Biotherapeutics Inc

11.81

-38.63%

82.94M

Performance Decomposition

Market capitalization of IKT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IKT in the past 1 year is driven by Unknown.